Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study
Thomas E. Witzig(WinnMed), Antonio Gualberto(Kura Oncology (United States)), Raquel de Oña(MD Anderson Cancer Center Madrid), James A. Bolognese(Cytel (United States)), Robert C. Curry(Kura Oncology (United States)), Antonia Rodríguez Izquierdo(Hospital Universitario 12 De Octubre), Lubomir Sokol(Moffitt Cancer Center), Ranjana H. Advani(Stanford Medicine), Catherine Scholz(Kura Oncology (United States)), María José Terol(Hospital Clínico Universitario de Valencia), Miguel Á. Piris(Hospital Universitario Fundación Jiménez Díaz), Marta Rodríguez(Hospital Universitario Fundación Jiménez Díaz), Jose Maria Roncero, Eric D. Jacobsen(Dana-Farber Cancer Institute), Linda Kessler(Kura Oncology (United States)), Vishnu S. Mishra(Kura Oncology (United States)), Francine M. Foss(Yale Cancer Center), Won-Seog Kim(Samsung Medical Center), Michael R. Kurman(Kura Oncology (United States)), Maria de Fatima De La Cruz(Hospital Universitario Virgen del Rocío), Ana Marín‐Niebla(Vall d'Hebron Hospital Universitari), Dolores Caballero(Complejo Hospitalario de Salamanca), Eva Domingo‐Doménech
Cited by 10
Related Papers
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
|Nature|2011|1.5k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
|New England Journal of Medicine|2018|1.1k